LSTA
LISATA THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.02
+0.99%Oct 14, 2026, 20:34 UTC
Lisata Therapeutics appointed Jeffrey Farrow as an independent Class III director and Audit Committee member, effective October 13, 2026.
Source:Oct 8, 2026, 12:00 UTC
The United States Patent and Trademark Office granted Lisata Therapeutics a method-of-use patent for certepetide for treating pancreatic cancer and other solid tumors.
Oct 5, 2026, 12:00 UTC
Marea Therapeutics, a subsidiary of Lisata Therapeutics, dosed the first patient in a Phase 2 clinical trial of MAR002 for the treatment of acromegaly.
Sep 24, 2026, 13:09 UTC
Marea Therapeutics, a subsidiary of Lisata Therapeutics, announced that Phase 2b TYDAL study data for its lead candidate MAR001 will be presented in a late-breaking science session at the American Heart Association Scientific Sessions 2026 in Chicago.
Source:Sep 17, 2026, 13:31 UTC
Lisata Therapeutics, Inc. agreed to sell 150,867.995 shares of Series C Preferred Stock in a private placement for an aggregate purchase price of approximately $225 million, with closing expected on September 18, 2026.
Sep 17, 2026, 13:31 UTC
Lisata Therapeutics, Inc. acquired Marea Therapeutics, Inc. through a two-step merger, issuing 1,793,129 common shares and 211,365.213 Series C Non-Voting Convertible Preferred Shares to Marea stockholders.
Aug 4, 2026, 11:00 UTC
Lisata Therapeutics filed a lawsuit against Kuva Labs Inc. and its subsidiary seeking damages for the benefit of its stockholders following the termination of a merger agreement.
Aug 4, 2026, 00:00 UTC
Lisata Therapeutics announced the termination of Dr. Kristen K. Buck as Executive Vice President of R&D and Chief Medical Officer, effective August 3, 2026, with severance benefits.
Aug 4, 2026, 00:00 UTC
Lisata Therapeutics granted James Nisco, Senior Vice President of Finance and Treasury and Chief Accounting Officer, a $200,000 gross cash retention bonus for continued employment through December 31, 2026.
Jul 17, 2026, 00:00 UTC
Lisata Therapeutics amended its merger agreement with Kuva Labs Inc. and Kuva Acquisition Corp., extending the outside date from July 17, 2026 to July 21, 2026.
Jun 10, 2026, 12:00 UTC
Kuva Labs Inc. commenced a tender offer to acquire Lisata Therapeutics for $4.00 per share in cash plus contingent value rights.
Jun 9, 2026, 00:00 UTC
Lisata Therapeutics, Kuva Labs Inc., and Kuva Acquisition Corp. amended their merger agreement, extending the tender offer commencement deadline and the outside closing date.